Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25873158 | 0.88 | LMNA (0.47) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL3680356 | 0.76 | LMNA (0.67) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL25873192 | 0.76 | MAPT (0.45) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL25873137 | 0.74 | HNF4A (0.43) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL6425848 | 0.74 | LMNA (0.51) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL3680354 | 0.73 | LMNA (0.62) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL16984663 | 0.72 | MAOA (0.48) | MAPTKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL22379484 | 0.70 | MAOA (0.43) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL27876722 | 0.70 | LMNA (0.50) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL12424999 | 0.70 | CA1 (0.41) | LMNAMAPTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11706982-B2 | Fused polycyclic compound, and preparation method and use thereof | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11706982-B2 | Fused polycyclic compound, and preparation method and use thereof | INF2, INTS9, PYM1 | LMNA 413/4885MAPT 955/4885KMT2A 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.